Datwyler

Datwyler's H1 2025: Healthcare recovery

22/07/25 -"While sales were slightly below the consensus (-1.2%) at CHF 563m, EBIT was 7% above the consensus at CHF 68.9m, driven by demand recovery in the healthcare division. The company highlighted that ..."

PDF page sample
Pages
48
Language
English
Published on
22/07/25
Download
You may also be interested by these reports :
22/07/25
While sales were slightly below the consensus (-1.2%) at CHF 563m, EBIT was 7% above the consensus at CHF 68.9m, driven by demand recovery in the ...
22/07/25
Bossard delivered 7.6% sales growth in H1 2025, driven by acquisitions, but organic growth declined (-1.3%). While Asia showed solid demand, Europe ...
22/07/25
Alfa Laval’s Q2 results missed the Visible Alpha consensus on orders and revenues. Orders suffered from normalisation in Marine, whereas revenues ...
22/07/25
Sale of the Russian subsidiary results in a loss of around EUR 120mn – Preview for 2Q25: Solid order intake, expected EBIT margin of 8.2%

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO